Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
ProMIS Neurosciences Inc
PMN
Healthcare
Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine...
applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:PMN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
•••
Jonathon Brown
X
View Profile
View Bullboard History
Post by
Jonathon Brown
on Apr 30, 2024 4:19pm
@ the Bell: Could the TSX keep hold of recent gains?
The biggest drag on the TSX was sustained by the heavyweight energy and mining sectors, while industrials and utilities also fell.
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 30, 2024 7:00am
New Press Release - ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 30, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody...
read article.
Lancaster Resources Receives Drill Permit Approval for Alkali Flat Lithium Brine Project
posted Apr 30, 2024 9:00am by
Lancaster Resources Inc.
-
|
"The approval of our maiden drilling application is confirmation of our commitment to responsible, minimal impact exploration and the last major hurdle before launching our maiden drilling program at Alkali Flat," says Andrew Watson, Lancaster's VP Engineering & Operations. "We are one step closer to drilling the first well at Alkali Flat and proving the ...read more
(95)
•••
goldtech
X
View Profile
View Bullboard History
Post by
goldtech
on Apr 29, 2024 3:40pm
TOXIC OLIGOMERS / JUNE DATA
The incidence of Alzheimer's disease (AD) is growing every day and finding an effective treatment is becoming more vital. Amyloid-β (Aβ) has been the focus of research for several decades. The
...more
(95)
•••
goldtech
X
View Profile
View Bullboard History
Post by
goldtech
on Apr 29, 2024 4:25am
Prothena
Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease. I don't know how you can
...more
(1)
•••
farmerlucy
X
View Profile
View Bullboard History
Comment by
farmerlucy
on Apr 28, 2024 5:39pm
RE:RE:1A Results/Market Awareness
A deal with a Pharma company that could leverage Promis's platform, Alzhemers might not work out, perhaps ALS , PD, vaccines have a better shot. Diagnostics clearly heading into alzheimers
...more
(107)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Apr 28, 2024 5:17pm
RE:RE:1A Results/Market Awareness
Yup, 1A unlikely to be a market mover. I cannot imagine the investor out there sitting on 1a results. Granted Pfizer made a killing (literal and figurative) with a "vaccine"
...more
(1)
•••
farmerlucy
X
View Profile
View Bullboard History
Comment by
farmerlucy
on Apr 28, 2024 5:01pm
RE:1A Results/Market Awareness
I wish you were right but the fact is Promis over the last couple of years has just been testing animals and humans not alzheimers patients. Numerous companies have passed phase 1 safety results
...more
(95)
•••
goldtech
X
View Profile
View Bullboard History
Post by
goldtech
on Apr 28, 2024 11:25am
1A Results/Market Awareness
When the 1A results are released in June the market will begin to put us on their radar screen and news letter writers will comment to their clients. Our ridiculous market cap will be gone and
...more
(107)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Apr 26, 2024 11:42pm
RE:RE:RE:The only scenario
I wasn't aware I had a conspiracy theory, how does it go?
(95)
•••
goldtech
X
View Profile
View Bullboard History
Comment by
goldtech
on Apr 26, 2024 7:39pm
RE:RE:The only scenario
Partnership, joint venture, collaboration, call it what you want but if we succeed then credits will be afforded to the entire platform. This all stems on the two scenarios and if successful, big
...more
(107)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Apr 26, 2024 5:09pm
RE:The only scenario
Is that from your belief about Boston Group's ROI timeline or why else do you rule out any sort of partnership, equity swap, license deal etc.? I disagree regardless because I don'
...more
(95)
•••
goldtech
X
View Profile
View Bullboard History
Post by
goldtech
on Apr 26, 2024 4:53pm
The only scenario
There is only two outcomes, success with the antibody or failure, end of story. If they succeed, instant buyout, if not, and empty public shell. Now everything points to an interesting outcome.
(107)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Apr 26, 2024 1:30pm
RE:RE:Bottom line
Or, (and this is an analogy so don't censor me again) instead of talking about how we modified the trial protocol to appease the dog humpers, we start talking about how many years ago we told them
...more
(107)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Apr 26, 2024 1:16pm
RE:Bottom line
Lol, not likely. Once you meet a bully's first condition you don't get respect, you get the next condition.
(95)
•••
goldtech
X
View Profile
View Bullboard History
Post by
goldtech
on Apr 26, 2024 11:38am
Bottom line
So if we assume that the timeline and present data is correct , then by June 2025 we will be in a bidding war for PMN. Show that you can achieve efficacy without Aria E and Big pharma will be at the
...more
(120)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Apr 26, 2024 5:47am
RE:RE:RE:No News
Hoping for a lower dose of PMN-310 to be successful enough that could lead to subcutaneous (injection) dosing of AZ patients in place of intravenous. Makes it easier for patients and presumable less
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Mullen Group Ltd. Reports 2024 First Quarter Financial Results
This Gambling Tech Stock is Future-Proofing the World’s Casinos and has No Direct Competition
Silvercorp to Acquire Adventus, Creating a Geographically Diversified Mining Company
Revolutionary Tech Company Announces Fourth Quarter and Full Year 2023 Results
Drill Permit Approval Received for New Mexico Lithium Project
This profitable gold stock is on its way up